Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Felip E, et al. Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB–IIIA NSCLC. In: Presidential symposium 3; September 20th, 2021. Presentation LBA9. Annals of Oncology 2021;32(suppl_5):S1283–346. https://doi.org/10.1016/annonc/annonc741.
2. Felip E, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet 2021. https://doi.org/10.1016/S0140-6736(21)02098-5
3. Altorki N, Felip E, Zhou C, et al. IMpower010: characterization of stage IB–IIIA NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab. In: International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer; September 8–14, 2021; virtual. Abstract PL02.05.
4. Zhou C, et al. IMpower010: biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB–IIIA NSCLC. In: Proffered Paper session 1; 2O – IMpower010; December 9th, 2021. Annals of Oncology 2021;32(suppl_7):S1373–91. https://doi.org/10.1016/annonc/annonc784.
5. Gogishvili M, et al. Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). In: Mini oral session – NSCLC, metastatic; September 19th, 2021. Presentation LBA51. Annals of Oncology 2021;32(suppl_5):S1283–346. https://doi.org/10.1016/annonc/annonc741.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ESMO 2021;memo - Magazine of European Medical Oncology;2022-06